Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: objective The management of children with congenital adrenal hyperplasia (CAH) remains a challenge, especially with regard to growth potentials. The objective of our analysis was to uncover the factors that influence the growth and final height of patients with CAH. design The linear growth pattern and body mass index (BMI) at different developmental stages (birth to 2 years, 2 years to puberty initiation and puberty initiation to final height) and the final height achieved were analysed retrospectively in 48 patients with 21‐hydroxylase deficiency; 17 with the salt‐wasting (SW) form, 25 with the simple virilizing (SV) and six with the nonclassical (NC) form. results Mean final height (FH) and FH‐SDS were, respectively, 170·8 ± 5·6 m and −0·57 ± 0·8 in males and 156·7 ± 6 cm and −0·61 ± 1 in females with the SW form, 166·1 ± 6·1 cm and −1·05 ± 1 in males and 151·6 ± 5·4 cm and −1·4 ± 1 in females with the SV form and 159·7 ± 6·9 cm and 0·3 ± 1·4 in females with the NC form. In subjects with the SW form, height SDS at 2 years, at puberty initiation and at FH were −0·18 ± 0·9, 0·11 ± 1·28 and −0·6 ± 1·0, respectively. FH achieved was not different from target height (TH) in the SW group, but it was significantly lower than TH in the SV group (P = 0·003). FH in the SW group showed a positive correlation to the height achieved at 2 years of age (r = 0·68, P = 0·019), and height at 2 years was negatively related to the hydrocortisone dose in the birth to 2‐year period (r = −0·79, P = 0·011). FH showed no correlation to hydrocortisone dose at any of the three developmental periods studied. BMI‐SDS were not different in the various forms of CAH and showed no correlation to FH or hydrocortisone dose. Age at menarche was comparable to that in our general population. conclusions Under our conditions of management, the final height of patients with the salt‐wasting form was comparable to the target height and to the most favourable literature data. The patients with the simple virilizing form fare less well, mainly due to delayed diagnosis and consequent advancement of bone age and early puberty. In salt‐wasting patients, height at 2 years is comparable to normals, it is influenced by the hydrocortisone dose and is related to the final height. Some height is lost during puberty. Hence, monitoring treatment over the first 2 years and during puberty is critical for the outcome in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess
New, M. I., & Wilson, R. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12790 · Cited by 164 · cited 1×
“…et al. © 2002 Blackwell Publishing Ltd, Clinical Endocrinology , 57 , 669–676 (Appan et al ., 1989; Young et al ., 1989; Brook, 1990; Cutler & Laue, 1990; Helleday et al ., 1993; Laue et al ., 1996; Merke & Cutler, 1997, 2001; Cornean et al ., 1998; New & Wilson, 1999; White & Speiser, 2000).”
Girgis, R., & Winter, J. S. D. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4320 · Cited by 139 · cited 1×
“An analogous effect was also demonstrated by a recent study by Girgis and Winter (1997).”
ResultObesity in 21-hydroxylase deficient patients
Cornean, R. E., Hindmarsh, P. C., & Brook, C. G. D. (1998) · Archives of Disease in Childhood · doi:10.1136/adc.78.3.261 · Cited by 135
Charmandari, E., Hindmarsh, P. C., Johnston, A., & Brook, C. G. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7522 · Cited by 134 · cited 1×
“Alternatively, suboptimal height gain at puberty might result from noncompliance or failure to adjust treatment to the changing body composition, or to alterations in cortisol pharmacokinetics during puberty (Charmandari et al., 2001).”
BackgroundHoimes‐Walker, D. J., Conway, G. S., Honour, J. W., Rumsby, G., & Jacobs, H. S. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02034.x · Cited by 134
Helleday, J. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.933 · Cited by 111 · cited 1×
“…final height are most likely to be age at puberty initiation and pubertal height gain, as also suggested by published data (Klingensmith et al., 1977; Appan et al., 1989; Helleday et al., 1993; Sandrini et al., 1993; Kleerekoper et al., 1997; Premawardhana et al., 1997; Migeon & Wisniewski, 2001).”
ResultDACOU‐VOUTETAKIS, C., & KARIDIS, N. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb43873.x · Cited by 49 · cited 1×
“Analogous data have been reported by other authors (Pescovitz et al., 1985; Tanae et al., 1988; Dacou-Voutetakis & Karidis, 1993; HolmesWalker et al., 1995; Merke & Cutler, 1997, 2001; Soliman et al., 1997; New et al., 1999).”
ResultSelf-citation
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Metadata
- Authors
- Manoli, I., Kanaka‐Gantenbein, C., Voutetakis, A., Maniati‐Christidi, M., & Dacou‐Voutetakis, C.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2002-10-22
- Volume
- 57
- Issue
- 5
- Pages
- 669-676
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2099933339
- Cited by
- 100
- References
- 8
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. https://app.cochat.ai/papers/10.1046/j.1365-2265.2002.01645.x
- The paper
- Manoli, I., Kanaka‐Gantenbein, C., Voutetakis, A., Maniati‐Christidi, M., & Dacou‐Voutetakis, C. (2002). Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2002.01645.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.